Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02104752 · ClinicalTrials.gov registry record · Phase 1
Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia
A Phase 1 study, sponsored by VA Greater Los Angeles Healthcare System.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT02104752 is a Phase 1 study that has completed, run by VA Greater Los Angeles Healthcare System. The registered enrollment target is 39 participants.
The verdict
NCT02104752, a Phase 1 study, has completed, sponsored by VA Greater Los Angeles Healthcare System.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
The investigators propose to test whether curcumin nanoparticles will improve behavioral measures and biomarkers of cognition and neuroplasticity in patients with schizophrenia who are already receiving a stable dose of antipsychotic.
Interventions
- DRUG Placebo
- DRUG Curcumin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2014-07 |
| Est. Completion | 2017-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02104752
The ClinicalTrials.gov registry entry for NCT02104752 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Greater Los Angeles Healthcare System, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02104752 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02104752 about?
NCT02104752 is a clinical study titled "Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia". The investigators propose to test whether curcumin nanoparticles will improve behavioral measures and biomarkers of cognition and neuroplasticity in patients with schizophrenia who are already receiving a stable dose of antipsychotic.
What is the current status of trial NCT02104752?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2014-07. Estimated completion is 2017-10.
What interventions are being tested in trial NCT02104752?
The interventions under investigation include: Placebo (DRUG), Curcumin (DRUG).
Who is sponsoring clinical trial NCT02104752?
This trial is sponsored by VA Greater Los Angeles Healthcare System, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.